Advances in the treatment of Crohn's disease

Gastroenterology

Volumn 126, Issue 6, 2004, Pages 1574-1581

  Egan, Laurence J ^a   Sandborn, William J ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; AZATHIOPRINE; BUDESONIDE; CERTOLIZUMAB PEGOL; CORTICOSTEROID; ETANERCEPT; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; METRONIDAZOLE; NATALIZUMAB; OLSALAZINE; SALAZOSULFAPYRIDINE; TACROLIMUS; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ANUS FISTULA; CROHN DISEASE; DRUG EFFICACY; DRUG INFUSION REACTION; EVIDENCE BASED MEDICINE; HUMAN; LIVER TOXICITY; LYMPHOMA; MAINTENANCE THERAPY; OPPORTUNISTIC INFECTION; PANCREATITIS; PERIANAL ABSCESS; PERIANAL CROHN DISEASE; PHARMACOGENOMICS; PNEUMONIA; PRIORITY JOURNAL; RASH; REMISSION; REVIEW;

EID: 2442550570     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2004.01.062     Document Type: Article

References (58)

1. Malchow H, Ewe K, Brandes JW, Goebell H, Ehms H, Sommer H, Jesdinsky H. European Cooperative Crohn's Disease Study (EC-CDS): results of drug treatment. Gastroenterology 1984;86:249-266.
2. Summers RW, Switz DM, Sessions JT Jr, Becktel JM, Best WR, Kern F Jr, Singleton JW. National Cooperative Crohn's Disease Study: results of drug treatment. Gastroenterology 1979;77:847-869.
3. Campieri M, Ferguson A, Doe W, Persson T, Nilsson LG. Oral budesonide is as effective as oral prednisolone in active Crohn's disease. The Global Budesonide Study Group. Gut 1997;41:209-214.
4. Greenberg GR, Feagan BG, Martin F, Sutherland LR, Thomson AB, Williams CN, Nilsson LG, Persson T. Oral budesonide for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group. N Engl J Med 1994;331:836-841.
5. Rutgeerts P, Lofberg R, Malchow H, Lamers C, Olaison G, Jewell D, Danielsson A, Goebell H, Thomsen OO, Lorenz-Meyer H, Hodgson H, Persson T, Seidegard C. A comparison of budesonide with prednisolone for active Crohn's disease. N Engl J Med 1994;331:842-845.
6. Thomsen OO, Cortot A, Jewell D, Wright JP, Winter T, Veloso FT, Vatn M, Persson T, Pettersson E. A comparison of budesonide and mesalamine for active Crohn's disease. International Budesonide-Mesalamine Study Group. N Engl J Med 1998;339:370-374.
7. Tremaine WJ, Hanauer SB, Katz S, Winston BD, Levine JG, Persson T, Persson A. Budesonide CIR capsules (once or twice daily divided-dose) in active Crohn's disease: a randomized placebo-controlled study in the United States. Am J Gastroenterol 2002;97:1748-1754.
8. Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T, DeWoody KL, Schaible TF, Rutgeerts PJ. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997;337:1029-1035.
9. Steinhart AH, Feagan BG, Wong CJ, Vandervoort M, Mikolainis S, Croitoru K, Seidman E, Leddin DJ, Bitton A, Drouln E, Cohen A, Greenberg GR. Combined budesonide and antibiotic therapy for active Crohn's disease: a randomized controlled trial. Gastroenterology 2002;123:33-40.
10. Turunen U, Farkkila M, Hakala K, Vuoristo M, Rahm V, Seppala K, Valtonen V, Miettinen TA. Ciprofloxacin treatment combined with conventional therapy in Crohn's disease. A prospective, double blind, placebo-controlled study. Gut 1995;37:A193.
11. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, Rachmilewitz D, Wolf DC, Olson A, Bao W, Rutgeerts P. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002;359:1541-1549.
12. Schreiber S, Rutgeerts P, Fedorak RN, Khallq-Kareemi M, Kamm MA, Patel J. CDP870, a humanized and -TNF antibody fragment, Induces clinical response with remission in patients with active Crohn's disease. Gastroenterology 2003;124:A468.
13. Sandborn WJ, Feagan BG, Hanauer SB, Present DH, Sutherland LR, Kamm MA, Wolf DC, Baker JP, Hawkey C, Archambault A, Bernstein CN, Novak C, Heath PK, Targan SR. An engineered human antibody to TNF (CDP571) for active Crohn's disease: a randomized double-blind placebo-controlled trial. Gastroenterology 2001;120:1330-1338.
14. Sandbom WJ, Feagan B, Radford-Smith G, Kovacs A, Enns R, Patel J. A randomized placebo controlled trial of CDP571, a humanized monoclonal antibody to TNF-α, in patients with moderate to severe Crohn's disease. Gastroenterology 2003;124: A469.
15. Ghosh S, Goldin E, Gordon FH, Malchow HA, Rask-Madsen J, Rutgeerts P, Vyhnalek P, Zadorova Z, Palmer T, Donoghue S. Natalizumab for active Crohn's disease. N Engl. Med 2003;348:24-32.
16. Gordon FH, Lai CW, Hamilton MI, Allison MC, Srivastava ED, Fouweather MG, Donoghue S, Greenlees C, Subhani J, Amlot PL, Pounder RE. A randomized placebo-controlled trial of a humanized monoclonal antibody to α4 integrin in active Crohn's disease. Gastroenterology 2001;121:268-274.
17. Elan and Biogen Idec announce ANTEGREN-natalizumab-phase III maintenance trial in Crohn's disease met its primary endpoint. Internet press release, 2004. Available at: http:// www.elan.com/News/full.asp?ID=489377.
18. Feagan BG, Rochon J, Fedorak RN, Irvine EJ, Wild G, Sutherland L, Steinhart AH, Greenberg GR, Gillies R, Hopkins M, Hanauer SB, McDonald JWD. Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators. N Engl J Med 1995;332:292-297.
19. Candy S, Wright J, Gerber M, Adams G, Gerig M, Goodman R. A controlled double blind study of azathioprine in the management of Crohn's disease. Gut 1995;37:674-678.
20. Present DH, Korelitz BI, Wisch N, Glass JL, Sachar DB, Pasternack BS. Treatment of Crohn's disease with 6-mercaptopurine. A long-term, randomized, double-blind study. N Engl J Med 1980;302:981-987.
21. Markowitz J, Grancher K, Kohn N, Lesser M, Daum F. A multi-center trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease. Gastroenterology 2000;119:895-902.
22. Baert F, Noman M, Vermeire S, Van Assche G, D'Haens G, Carbonez A, Rutgeerts P. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003;348:601-608.
23. Sandborn WJ. Preventing antibodies to infliximab in patients with Crohn's disease: optimize not immunize. Gastroenterology 2003;124:1140-1145.
24. Korelitz BI, Hanauer S, Rutgeerts P, Present DH, Peppercorn MA. Post-operative prophylaxis with 6-MP, 5-ASA or placebo in Crohn's disease: a 2-year multicenter trial. Gastroenterology 1998;114:A1011.
25. Lemann M, Bouhnik Y, Colombel JF, Duclos B, Soule JC, Lerebours E, Mary JY, Modigliani R. Randomized double blind placebo-controlled multicenter azathioprine withdrawal trial in Crohn's disease. Gastroenterology 2002;122:A174.
26. Arber N, Odes HS, Fireman Z, Lavie A, Broide E, Bujanover Y, Becker S, Pomerantz I. Moshkowitz M, Patz J. A controlled double blind multicenter study of the effectiveness of 5-aminosalicylic acid In patients with Crohn's disease in remission. J Clin Gastroenterol 1995;20:203-206.
27. Gendre JP, Mary JY, Florent C, Modigliani R, Colombel JF, Soule JC, Galmiche JP, Lerebours E, Descos L, Viteau JM, Rene E, Metman EH, Bories P, Bremondy A, Bouvry M, Lamouliatte H, Gineston JL. Oral mesalamine (Pentasa) as maintenance treatment in Crohn's disease: a multicenter placebo-controlled study. The Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives (GETAID). Gastroenterology 1993;104:435-439.
28. Prantera C, Pallone F, Brunetti G, Cottone M, Milgioli M. Oral 5-aminosalicylic acid (Asacol) in the maintenance treatment of Crohn's disease. The Italian IBD Study Group. Gastroenterology 1992;103:363-368.
29. Modigliani R, Colombel JF, Dupas JL, Dapolgny M, Costil V, Veyrac M, Duclos B, Soule JC, Gendre JP, Galmiche JP, Darme O, Cadiot G, Lamouliatte H, Belaiche J, Mary JY. Mesalamine in Crohn's disease with steroid-induced remission: effect on steroid withdrawal and remission maintenance, Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives. Gastroenterology 1996;110:688-693.
30. Brignola C, lannone P, Pasquali S, Campieri M, Gionchetti P, Belluzzi A, Basso O, Miglioli M, Barbara L. Placebo-controlled trial of oral 5-ASA in relapse prevention of Crohn's disease. Dig Dis Sci 1992;37:29-32.
31. Sutherland LR, Martin F, Bailey RJ, Fedorak RN, Poleski M, Dallaire C, Rossman R, Saibil F, Lariviere L. A randomized, placebo-controlled, double-blind trial of mesalamine in the maintenance of remission of Crohn's disease. The Canadian Mesalamine for Remission of Crohn's Disease Study Group. Gastroenterology 1997;112:1069-1077.
32. International Mesalazine Study Group. Coated oral 5-aminosalicylic acid versus placebo in maintaining remission of Inactive Crohn's disease. Aliment Pharmacol Ther 1990;4:55-64.
33. Thomson AB, Wright JP, Vatn M, Bailey RJ, Rachmilewitz D, Adler M, Wilson-Lynch KA. Mesalazine (Mesasal/Claversal) 1.5 g b.d. vs. placebo in the maintenance of remission of patients with Crohn's disease. Aliment Pharmacol Ther 1995;9:673-683.
34. de Franchis R, Omodei P, Ranzi T, Brignola C, Rocca R, Prada A, Pera A, Vecchi M, Del Piano M, Ferrara A, Belloli C, Piodi L, Framarin L, Astegiano M, Riccioll FA, Meucci G. Controlled trial of oral 5-aminosalicylic acid for the prevention of early relapse In Crohn's disease. Aliment Pharmacol Ther 1997;11:845-852.
35. Lochs H, Mayer M, Fleig WE, Mortensen PB, Bauer P, Genser D, Petritsch W, Raithel M, Hoffmann R, Gross V, Plauth M, Staun M, Nesje LB. Prophylaxis of postoperative relapse In Crohn's disease with mesalamine: European Cooperative Crohn's Disease Study VI. Gastroenterology 2000;118:264-273.
36. Lennard-Jones JE. Sulphasalazine in asymptomatic Crohn's disease. A multicentre trial. Gut 1977;18:69-72.
37. Mahmud N, Kamm MA, Dupas JL, Jewell DP, O'Morain CA, Weir DG, Kelleher D. Olsalazine is not superior to placebo In maintaining remission of inactive Crohn's colitis and ileocolitis: a double blind, parallel, randomised, multicentre study. Gut 2001;49:552-556.
38. Greenberg GR, Feagan BG, Martin F, Sutherland LR, Thomson AB, Williams CN, Nilsson LG, Persson T. Oral budesonide as maintenance treatment for Crohn's disease: a placebo-controlled, dose-ranging study. Canadian Inflammatory Bowel Disease Study Group. Gastroenterology 1996;110:45-51.
39. Lofberg R, Rutgeerts P, Malchow H, Lamers C, Danlelsson A, Olaison G, Jewell D, Ostergaard Thomsen O, Lorenz-Meyer H, Goebell H, Hodgson H, Persson T, Seldegard C. Budesonide prolongs time to relapse in ileal and ileocaecal Crohn's disease. A placebo controlled one-year study. Gut 1996;39:82-86.
40. Ferguson A, Campieri M, Doe W, Persson T, Nygard G. Oral budesonide as maintenance therapy In Crohn's disease-results of a 12-month study. Global Budesonide Study Group. Aliment Pharmacol Ther 1998;12:175-183.
41. Mantzaris GJ, Petraki K, Sfakianakis M, Archavlis E, Christidou A, Chadio-Iordanides H, Triadaphyliou G. Budesonide versus mesalamine for maintaining remission in patients refusing other immunomodulators for steroid-dependent Crohn's disease. Clin Gastroenterol Hepatol 2003;1:122-128.
42. Cortot A, Colombel JF, Rutgeerts P. Lauritsen K. Malchow H, Hamling J, Winter T, Van Gossum A, Persson T, Pettersson E. Switch from systemic steroids to budesonide In steroid dependent patients with inactive Crohn's disease. Gut 2001;48:186-190.
43. Green JR, Lobo AJ, Gieffer M, Travis S, Watkins HC. Maintenance of Crohn's disease over 12 months: fixed versus flexible dosing regimen using budesonide controlled ileal release capsules. Aliment Pharmacol Ther 2001;15:1331-1341.
44. Stockbrugger RW, Schoon E, Bollani S, Israeli E, Persson T, Bentgsson B, Persson A, Graffner H. Budesonide versus prednisolone In the management of Crohn's disease: a randomized multinational 2-year study. Gastroenterology 2003;124:A181.
45. Rutgeerts P, Hiele M, Geboes K, Peeters M, Penninckx F, Aerts R, Kerremans R. Controlled trial of metronidazole treatment for prevention of Crohn's recurrence after ileal resection. Gastroenterology 1995;108:1617-1621.
46. Feagan BG, Fedomk RN, Irvine EJ, Wild G, Sutherland L, Steinhan AH, Greenberg GR, Koval J, Wong CJ, Hopkins M, Hanauer SB, McDonald JW. A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators. N Engl J Med 2000;342:1627-1632.
47. Sandbom WJ, Feagan BG. Review article: mild to moderate Crohn's disease-defining the basis for a new treatment algorithm. Aliment Pharmacol Ther 2003;18:263-277.
48. Munkholm P, Langholz E, Davidsen M, Binder V. Frequency of glucocorticoid resistance and dependency in Crohn's disease. Gut 1994;35:360-362.
49. Faubion WA Jr, Loftus EV Jr, Harmsen WS, Zinsmelster AR, Sandborn WJ, Munkholm P, Langholz E, Davidsen M, Binder V. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 2001;121:255-260.
50. Olaison G, Smedh K, Sjodahl R. Natural course of Crohn's disease after ileocolic resection: endoscopically visualised ileal ulcers preceding symptoms. Gut 1992;33:331-335.
51. Rutgeerts P, Geboes K, Vantrappen G, Beyls J, Kerremans R, Hiele M. Predictability of the postoperative course of Crohn's disease. Gastroenterology 1990;99:956-963.
52. Schwartz DA, Loftus EV Jr, Tremaine WJ, Panacclone R, Harmsen WS, Zinsmeister AR, Sandbom WJ. The natural history of fistulizing Crohn's disease in Olmsted County, Minnesota. Gastroenterology 2002;122:875-880.
53. Schwartz DA, Pemberton JH, Sandbom WJ. Diagnosis and treatment of perianal fistulas in Crohn disease. Ann Intern Med 2001;135:906-918.
54. Schwartz DA, Wiersema MJ, Dudiak KM, Fletcher JG, Clain JE, Tremaine WJ, Zinsmeister AR, Norton ID, Boardman LA, Devine RM, Wolff BG, Young-Fadok TM, Diehl NN, Pemberton JH, Sandbom WJ. A comparison of endoscopic ultrasound, magnetic resonance imaging, and exam under anesthesia for evaluation of Crohn's perianal fistulas. Gastroenterology 2001;121:1064-1072.
55. Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, van Hogezand RA, Podolsky DK, Sands BE, Braakman T, DeWoody KL, Schaible TF, van Deventer SJ. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999;340:1398-1405.
56. Sandborn WJ, Present DH, Isaacs KL, Wolf DC, Greenberg E, Hanauer SB, Feagan BG, Mayer L, Johnson T, Galanko J, Martin C, Sandler RS. Tacrolimus for the treatment of fistulas in patients with Crohn's disease: a randomized, placebo-controlled trial. Gastroenterology 2003;125:380-388.
57. Sands BE, Van Deventer S, Bernstein CN, Kamm MA, Rachmilewitz D, Chey WY, Cashner BA, Wolf DC, Blank M, Wild G, Fedorak RN, Feagan B, Anderson F, Marsters P, Rutgeerts P. Long-term treatment of fistulizing Crohn's disease: response to infiximab in the ACCENT II trial through 54 weeks. Gastroenterology 2002;122:A671.
58. Weinshilboum R. Inheritance and drug response. N Engl J Med 2003;348:529-537.